Grant supports gene-editing research for rare metabolic diseases

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children’s Hospital of Philadelphia (CHOP).

Risk Adjusted Net Present Value: What is the current valuation of Pfizer’s Ibuzatrelvir

The revenue for Ibuzatrelvir is expected to reach an annual total of $21 mn by 2036 in the US based off GlobalData’s Expiry Model. The

December 17, 2024

Vidac secures funding to advance skin cancer trials of novel ointment – Pharmaceutical Technology

Actinic keratosis is a pre-cancerous area of thick, scaly, or crusty skin. Credit: Douglas Cliff via Shutterstock. Vidac Pharma has secured €600,000 ($645,651) in additional

November 7, 2024

FDA approves reformulated Covid boosters for fall season

The FDA cleared a new round of Covid-19 boosters from Moderna and Pfizer/BioNTech that this time target the KP.2 variant. The updated vaccines are expected

August 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.